Novartis details eczema win, autoimmune CAR-T efforts after rocky quarter
Novartis touted a mid-stage win for its eczema drug, revealed it is working toward restarting trials of its autoimmune CAR-T cell therapy and slightly trimmed the top of its sales-growth guidance through 2031. CEO Vas ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.